AIA Life Insurance Korea headquarters in Seoul / Courtesy of AIA Life Insurance

AIA Life Insurance Korea has strengthened its cancer insurance offering after receiving nine months of exclusive usage rights for a new rider covering advanced medical treatments, a move that signals growing recognition of next-generation therapies within Korea’s insurance industry and could broaden patients’ access to costly but potentially life-saving procedures, the insurer said Monday.

The company announced that its “Non-Participating Specific Advanced Medical Treatment Rider” was granted the exclusivity period by the Life Insurance Association of Korea.

In the Korean insurance market, exclusive usage rights are awarded only to products that meet strict evaluation standards in originality, usefulness, innovation and development effort.

A nine-month exclusivity period indicates that the product achieved high evaluation scores and prevents competitors from launching similar offerings during that time.

The rider is designed to expand the scope of traditional cancer insurance by incorporating coverage for emerging medical technologies that are increasingly used when conventional treatments are insufficient.

Specifically, the exclusivity recognition applies to coverage for percutaneous radiofrequency thermal ablation, percutaneous microwave thermal ablation and hyperthermic intraperitoneal chemotherapy.

These treatments are considered advanced alternatives that can help treat tumors in patients who cannot undergo surgery or who face a high risk of recurrence or metastasis.

By covering such procedures, AIA Life said the rider effectively extends protection beyond the conventional pillars of cancer treatment — surgery, medication and radiation therapy — allowing policyholders to consider a wider range of medical options as treatment technologies evolve.

The company also structured the coverage amounts based on real patient out-of-pocket medical cost data in an effort to reduce the financial burden associated with high-cost advanced therapies.

Source: Korea Times News